Dr. Reddy's Laboratories Announce Launch of Desmopressin Acetate Injection
The following is from a press release from Dr. Reddy’s Laboratories. Read the press release in its entirety here. Dr. Reddy’s Laboratories Ltd., along with its subsidiaries together referred to as “Dr. Reddy’s” today announced the launch of Desmopressin Acetate Injection USP, 4 mcg/mL Single-dose Ampules, a therapeutic equivalent generic version of DDAVP (desmopressin acetate) […]
Novo Nordisk Notice on COVID-19, Rebinyn® and Laboratory Assays
Novo Nordisk recently distributed a notice relevant to its product Rebinyn®, raising awareness that one-stage clotting assay results can be significantly affected by the type of activated partial thromboplastin time (aPTT) reagent used, which can result in over or under-estimation of Factor IX activity.The notice which was addressed to HTCs, physicians and other healthcare providers, includes […]
uniQure Presents New Preclinical Data in Hemophilia A
The following is an excerpt from a press release from uniQure. Read the press release in its entirety here. uniQure N.V., a gene therapy company advancing transformative therapies for patients with severe medical needs, presented new preclinical data on its gene therapy candidates AMT-150 for Spinocerebellar Ataxia type 3, AMT-190 for Fabry disease, and AMT-180 […]
Pfizer and BioNTech Dose First Participants in the COVID-19 Vaccine Development Program
The following is a press release from Pfizer. Read it in its entirety here. Pfizer Inc. and BioNTech SE announced the first participants have been dosed in the U.S. in the Phase 1/2 clinical trial for the BNT162 vaccine program to prevent COVID-19. The trial is part of a global development program, and the dosing […]
uniQure Announces Highlights of Recent Progress
The following is an excerpt from a press release from uniQure. Read the release in its entirety here. uniQure N.V., a gene therapy company advancing transformative therapies for patients with severe medical needs, reported recent progress across its business.“Despite the ongoing global crisis caused by the coronavirus pandemic, we ended the first quarter of 2020 […]
BioMarin Update on Impact of COVID-19 on Clinical Trials
The following information is provided by BioMarin to provide general information about its ongoing clinical trials in the context of the COVID-19 pandemic. “As more cases of COVID-19 are confirmed, we recognize the increased challenges and concerns faced by participants in the BioMarin Gene Therapy clinical studies. The safety and well-being of patients, healthcare providers, […]
Takeda Expands Patient Assistance in the U.S. During COVID-19 Crisis
Below is a letter from Takeda. “To our valued patients, customers and other stakeholders, As the COVID-19 crisis continues to unfold, Takeda’s Patient Assistance Response team is working around the clock to help ensure that the people who need our medicines and treatments can continue to access them safely and without interruption. Consistent with our commitment to […]
Spark and Roche Update on Hemophilia Gene Therapy Program
The following is an update on the Spark and Roche gene therapy program. “Together, Spark and Roche remain fully committed in our objective to meet the needs of the hemophilia community by developing gene therapies for hemophilia A that, with the lowest effective dose and optimal regimen to manage the immune system response, demonstrate safety, […]
Genentech Notice on COVID-19, Hemlibra®, and Laboratory Assays
Genentech recently distributed a notice relevant to its product Hemlibra®, reminding health care providers that it is known to interfere with certain laboratory assays used to measure blood coagulation. These tests are often used for patients with bleeding disorders such as hemophilia, and to diagnose and monitor individuals suffering from other conditions that affect coagulation […]
Bayer Letter on Product Availability During COVID-19
The following is a copy of a letter from Bayer. “For more than 30 years, Bayer has been providing FVIII therapies and support programs to people living with hemophilia A. As we all face the current coronavirus (COVID-19) outbreak, the health and safety of our patients continues to be a priority. We realize you may […]
English 
Español de Puerto Rico